We are gearing up for our annual AI in Drug Discovery summit in a few days. So, for this episode, we focused on some recent AI news coverage. First, GEN senior editor Fay Lin, PhD, visited Seattle recently for some AI-focused meetings. She discusses her experiences in the Emerald City, including an exclusive in-person interview with Nobel laureate, David Baker, PhD, on what’s real and what’s hype when it comes to using AI to design proteins de novo. Then we explore new research from University of California, San Diego, that used machine learning to identify gene networks that could be targeted to reprogram cancer stem cells. We also go over some early studies that point to a possible drug candidate for colon cancer.
Listed below are links to the GEN stories referenced in this episode of Touching Base:
Brunkow, Ramsdell, Sakaguchi Win Nobel Prize in Physiology or Medicine for Peripheral Immune Tolerance
Uduak Thomas, GEN, October 6, 2025
AI in Protein Design: Hype vs. Reality Explained by David Baker
By Fay Lin, PhD, GEN, October 20, 2025
Nobel Anniversary: David Baker Keynotes STEM Fundraiser by ARCS Foundation Seattle
By Fay Lin, PhD, GEN, October 14, 2025
AI Treatment Reprograms and Triggers Cancer Stem Cells to Self-Destruct
GEN, October 20, 2025
The State of AI in Drug Discovery Registration
Touching Base Podcast
Hosted by Corinna Singleman, PhD
Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD